About this survey


Thank you for participating.
 
This independent study by PatientView looks at the corporate reputation of the pharmaceutical industry—and that of 48 pharmaceutical companies—during the Covid pandemic of 2020.
 
You will be entitled to a free copy of the full results upon publication (April 2021), if you wish to receive them.
 
Note about the survey format:
  • If you are using a mobile/cell to answer the questionnaire, the survey is more easily completed when the mobile/cell is in LANDSCAPE.
When you finish this survey, your responses will not be registered until you click the “Done” button at the end of the this questionnaire.
If you have any questions about this survey, the email contact is at the end of the survey.

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* Would you like to comment on your answer?

Question Title

 

<div style="text-align: center;"> </div>

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* c.) What is the geographic remit of your organisation?

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* d.) Approximately how many patients did your organisation communicate/engage with in 2020?

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* e.) Below is a list of 48 top pharma companies worldwide.

Can you indicate which companies are familiar to your organisation, and with which companies has your organisation worked or partnered?

Please take the word ‘familiar’ to mean:
“Feeling knowledgeable enough about the company to be able to comment on its activities and products”.

  We are FAMILIAR with this company. We have WORKED or PARTNERED with this company.
AbbVie (including Allergan).
Acorda Therapeutics.
Almirall.
Amgen.
Astellas Pharma.
AstraZeneca.
Bayer.
Biogen.
Boehringer Ingelheim.
Bristol Myers Squibb (including Celgene).
Chiesi Farmaceutici.
CSL Behring.
Daiichi Sankyo.
Dr. Reddy's Laboratories.
Eisai.
Eli Lilly (Lilly).
Ferring.
Gedeon Richter.
Gilead Sciences (including Kite Pharma).
Grifols.
Grünenthal.
GSK.
Horizon Therapeutics.
Ipsen.
Janssen (including Actelion).
LEO Pharma.
Lundbeck.
Menarini.
Merck KGaA.
MSD (Merck Sharp & Dohme).
Mylan.
Novartis.
Novo Nordisk.
Octapharma.
Otsuka.
Pierre Fabre Laboratories.
Pfizer.
Roche.
Sandoz.
Sanofi (including Genzyme).
Servier.
Sun Pharma.
Takeda (including Shire).
Teva (known as Pliva in south-eastern European countries).
UCB.
Vertex Pharmaceuticals.
Vifor Pharma.
ViiV Healthcare.

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* f.) If your organisation works or partners with pharma companies:
What are the main types of working or partnering relationships your organisation has with pharma companies?

Question Title

 

<div style="text-align: center;"> </div>
Questions on Corporate Reputation

For the purposes of this survey, please regard the phrase 'corporate reputation' to be defined as:

"The extent to which pharmaceutical companies are meeting the expectations of patients and patient groups"

The survey has 14 main questions

Please skip any question that you cannot answer (or are irrelevant to your organisation).

Question Title

* FIRST, three questions about ...
the corporate reputation of the pharma industry as a whole


Question 1 of 14.
How do you think your organisation’s members (or the patients known to your organisation) would rate the corporate reputation of the following healthcare sectors in 2020?

  Excellent. Good. Fair. Poor. I do not know.
Biotechnology companies.
Generic drug manufacturers.
Health insurers (for-profit).
Health insurers (not-for-profit).
Medical-device companies.
Pharmaceutical companies (multinational).
Pharmacy Benefit Managers (PBMs)—if relevant in your country.
Private-sector healthcare services.
Retail pharmacists.

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* Question 2 of 14.
How "good" or "bad" do you think the pharmaceutical industry as a whole has been in 2020 at carrying out the following activities (all of which influence the industry's corporate standing with patients and patient groups)?

  Excellent. Good. Fair. Poor. I do not know.
Having a patient-centred strategy.
Providing high-quality information for patients.
Ensuring patient safety.
Being innovative.
Making products that are of benefit to patients.
Being transparent about company pricing policies.
Being transparent by sharing clinical data.
Being transparent by disclosing funding to stakeholders (such as doctors).
Acting with integrity.
Working in partnership with patient groups.
Providing patients with more services than just the provision of medicines.
Fair pricing policies (not making unseemly profits).
Helping patients to gain access to medicines.
Engaging patients/patient groups in company drug research/drug discovery (before clinical trials begin).
Engaging patients/patient groups in company drug development (including clinical trials, and after).
Adopting an ‘Environmental, Social, and Governance’ (ESG) agenda.

Question Title

 

<div style="text-align: center;"> </div>

Question Title

* Question 3 of 14.
How effective has the pharma industry as a whole been at tackling the Covid pandemic of 2020—from a patient perspective?

Question Title

 

<div style="text-align: center;"> </div>
Please click "Next", below, to move on to the main part of the survey.

T